Jinhua City Held Government-Enterprise Symposium Jiang Xiaomeng Talks about Post-Enterprise Epidemic Development
Release time:
2020-07-22
Jinhua City Convenes Government-Enterprise Symposium
Jiang Xiaomeng Talks about Post-Enterprise Epidemic Development
News
Jiang Xiaomeng said in his speech that due to the epidemic, the living environment of enterprises has been clearly polarized, that is, domestic demand-oriented enterprises, especially those with brand influence or advantages in e-commerce, have better survival and development; export-dependent enterprises are in trouble because they have lost a large number of foreign orders. Since the outbreak of the epidemic, the State has continuously introduced a series of fiscal, financial and taxation policies to increase government investment, especially in new infrastructure and infrastructure construction, to stimulate economic recovery. The "six stability and six protection" policy issued by the state and the recent "Building a Strong City of Private Economy and Innovation and Intelligent Development Conference" held in Jinhua City have brought a new round of opportunities, enterprises should seize and make good use of this opportunity, learn from past experiences and lessons, improve themselves, strengthen themselves and meet the future.
Talking about the development of enterprises in the post-epidemic era, Jiang Xiaomeng pointed out that the current "policy window period" is the most relaxed, preferential, clear and weighty. Enterprises should seize the opportunity in time, make good use of the relevant policies and measures issued by governments at all levels to deal with the epidemic and restore economic development, so as to create the best conditions for their own development ", strengthen their own" hematopoietic capacity ", in the post-epidemic era to do a good job of" subtraction "(minus unnecessary expenses, supporting the scene of the show, minus the unprofitable or low-profit business sector) and" addition "(in the industrial chain to seek" group "cooperation and low-cost mergers and acquisitions cooperation, looking for more development opportunities); third, to further build core competitiveness, products to master the core technology, the service must provide an experience that exceeds expectations, the brand must have its own core value, and at the same time closely integrate the Internet economy with its own industry to carry out transformation and upgrading. At the same time, it is also hoped that government departments will, on the basis of the policies introduced in the past, increase their assistance to enterprises hit by the epidemic, so as to achieve a combination of "universal" and "customization" to help enterprises form a synergy and get out of the predicament as soon as possible.
Lv Bing, member of the Standing Committee of Jinhua Municipal Party Committee and Deputy Mayor, Municipal Party Committee Office, Municipal Government Office, Municipal Development and Reform Commission, Municipal Federation of Industry and Commerce, Municipal Economic and Information Bureau, Municipal Finance Bureau, and other relevant persons in charge, as well as 30 Representatives of private entrepreneurs from Jinhua attended the meeting. Municipal Federation of Industry and Commerce Party Secretary Fang Weimin presided over the meeting. At the
meeting, Jiang Xiaomeng also awarded the municipal development and reform Commission a plaque of "face-to-face service, heart-to-heart connection between government and enterprise" on behalf of all private entrepreneurs. (below). (Reporter)

More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31